TR
EN
The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma
Abstract
Objective: Malignant mesothelioma is a rare and aggressive cancer. We aim to report our experience of stage 1 and 2 malign pleural mesothelioma (MPM) and investigate the prognostic factors.
Methods: We retrospectively reviewed 37 patients with clinical stage 1 and 2 MPM in our center and examined radiological findings, demographic characteristics, treatment modalities, survival, and recurrence.
Results: Eighteen of the 37 patients were male, and the mean age of the patients was 59.0 ± 11.2 years. Thirty patients had stage 1 MPM, and 7 patients had stage 2. Seven patients underwent surgery, and 30 patients received induction chemotherapy. Median progression-free survival (PFS) was 12.3 months (95% confidence interval [CI], 9.4-15.1), and the median overall survival (OS) was 24.3 months (95% CI, 15.8-32.8). In multivariate analysis, while gender and surgery had a statistically significant effect on PFS (p=0.01, p=0.01, respectively), both gender and surgery did not significantly affect OS (p=0.15, p=0.08, respectively). Local recurrence occurred in 28 patients, and 7 patients were presented with local recurrence and distant metastasis.
Conclusion: In our study, where the majority of patients were stage 1 and 2, the effect of the surgery was significant.
Keywords
References
- 1.Hiriart E, Deepe R, Wessels A. Mesothelium andMalignant Mesothelioma. J Dev Biol. 2019; 7.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
December 30, 2020
Submission Date
August 11, 2020
Acceptance Date
November 2, 2020
Published in Issue
Year 2020 Volume: 47 Number: 4
APA
Ocak, B., & Şahin, A. B. (2020). The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma. Dicle Medical Journal, 47(4), 770-778. https://doi.org/10.5798/dicletip.850203
AMA
1.Ocak B, Şahin AB. The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma. Dicle Medical Journal. 2020;47(4):770-778. doi:10.5798/dicletip.850203
Chicago
Ocak, Birol, and Ahmet Bilgehan Şahin. 2020. “The Benefit of Surgery on Survival for Patients With Stage 1 and 2 Malignant Pleural Mesothelioma”. Dicle Medical Journal 47 (4): 770-78. https://doi.org/10.5798/dicletip.850203.
EndNote
Ocak B, Şahin AB (December 1, 2020) The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma. Dicle Medical Journal 47 4 770–778.
IEEE
[1]B. Ocak and A. B. Şahin, “The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma”, Dicle Medical Journal, vol. 47, no. 4, pp. 770–778, Dec. 2020, doi: 10.5798/dicletip.850203.
ISNAD
Ocak, Birol - Şahin, Ahmet Bilgehan. “The Benefit of Surgery on Survival for Patients With Stage 1 and 2 Malignant Pleural Mesothelioma”. Dicle Medical Journal 47/4 (December 1, 2020): 770-778. https://doi.org/10.5798/dicletip.850203.
JAMA
1.Ocak B, Şahin AB. The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma. Dicle Medical Journal. 2020;47:770–778.
MLA
Ocak, Birol, and Ahmet Bilgehan Şahin. “The Benefit of Surgery on Survival for Patients With Stage 1 and 2 Malignant Pleural Mesothelioma”. Dicle Medical Journal, vol. 47, no. 4, Dec. 2020, pp. 770-8, doi:10.5798/dicletip.850203.
Vancouver
1.Birol Ocak, Ahmet Bilgehan Şahin. The benefit of surgery on survival for patients with stage 1 and 2 malignant pleural mesothelioma. Dicle Medical Journal. 2020 Dec. 1;47(4):770-8. doi:10.5798/dicletip.850203